Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings
Journal of Virology · 18.11.2026
DOI: 10.1128/jvi.01224-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, online erschienen am 18.11.2026. Verfasst von Maximilian A J Harman und 24 weiteren Autor:innen. Beteiligte Einrichtung: Bicycle Therapeutics, Cambridge, United Kingdom. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK, Medical Research Council, Wellcome Trust.
Abstract (Originalsprache)
The spread of respiratory viruses, such as influenza and SARS-CoV-2, has presented significant challenges over the last 30 years, with few effective therapeutic options available to this day. Bicyclic peptides represent a unique, modular modality in the antiviral armamentarium against future pandemics. This study utilizes tool molecules to provide a deeper evaluation of multivalent bicyclic (Bicycle) molecule efficacy in several preclinical SARS-CoV-2 challenge settings. We explore both pre-exposure prophylaxis and post-exposure therapeutic settings via subcutaneous and intranasal routes of administration. We contextualize this further in bespoke scenarios where the immune system is compromised, as well as viral transmission. Promisingly, in all studies, we observe efficacy, significantly reducing infectious viral burden at each study endpoint. These data further support the candidacy of Bicycle molecules as a differentiated antiviral therapeutic class in the context of pandemic preparedness. IMPORTANCE The COVID-19 pandemic triggered a rapid wave of innovation, accelerating the delivery of new vaccine technology and antiviral treatments. In our first paper, we described the discovery and molecular optimization of Bicycle molecules as a novel drug class for the potential treatment of SARS-CoV-2. Here, we have performed deeper characterization of these tool molecules in established animal models to evaluate scenarios for deployment, simulating SARS-CoV-2 transmission, testing more convenient delivery routes, such as intranasal, as well as looking at immunocompromised animals. The Bicycle molecules demonstrated positive outcomes in each of these studies and suggest that Bicycle molecules, as convenient and effective antiviral treatments, could be an important addition to help future preparedness against new viral pandemics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bicycle Therapeutics, Cambridge, United Kingdom.
- MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
- Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, Netherlands.
- Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Maximilian A J Harman, Katherine U Gaynor, Guido Papa, Simone Pellegrino, Gustavo Arruda Bezerra, Brian McGuinness, Phillip Jeffrey, Paul Beswick, Steven Stanway, Katerine Van Rietschoten, Liuhong Chen, Anna Albecka, Ieva Drulyte, Jo Herriott, Edyta Kijak, Eduardo Gallardo-Toledo, Lee Tatham, Parul Sharma, Eleanor Bentley, Jo Sharp, Adam Kirby, Leo C James, Andrew Owen, James P Stewart, Michael J Skynner
Förderung
- Innovate UK
- Medical Research Council
- Wellcome Trust
Zitieren
APA
Harman, M. A. J., Gaynor, K. U., Papa, G., Pellegrino, S., Bezerra, G. A., McGuinness, B., Jeffrey, P., Beswick, P., Stanway, S., Van Rietschoten, K., Chen, L., Albecka, A., Drulyte, I., Herriott, J., Kijak, E., Gallardo-Toledo, E., Tatham, L., Sharma, P., Bentley, E., …, & Skynner, M. J. (2026). Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings. Journal of Virology. https://doi.org/10.1128/jvi.01224-26
Vancouver
Harman MAJ, Gaynor KU, Papa G, Pellegrino S, Bezerra GA, McGuinness B, et al. Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings. Journal of Virology. 2026. doi:10.1128/jvi.01224-26
BibTeX
@article{Harman2026,
author = {Harman, Maximilian A J and Gaynor, Katherine U and Papa, Guido and Pellegrino, Simone and Bezerra, Gustavo Arruda and McGuinness, Brian and Jeffrey, Phillip and Beswick, Paul and Stanway, Steven and Van Rietschoten, Katerine and Chen, Liuhong and Albecka, Anna and Drulyte, Ieva and Herriott, Jo and Kijak, Edyta and Gallardo-Toledo, Eduardo and Tatham, Lee and Sharma, Parul and Bentley, Eleanor and Sharp, Jo and Kirby, Adam and James, Leo C and Owen, Andrew and Stewart, James P and Skynner, Michael J},
title = {Investigation of anti-SARS-CoV-2 multimeric bicyclic peptide inhibitors in a range of preclinical therapeutic settings},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.01224-26}
}
EUVIMED